L
15.24
-1.05 (-6.45%)
| Previous Close | 16.29 |
| Open | 16.35 |
| Volume | 2,146,906 |
| Avg. Volume (3M) | 1,216,314 |
| Market Cap | 476,859,104 |
| Price / Sales | 26.02 |
| Price / Book | 2.63 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2025 |
| Diluted EPS (TTM) | 0.660 |
| Total Debt/Equity (MRQ) | 0.62% |
| Current Ratio (MRQ) | 23.09 |
| Operating Cash Flow (TTM) | -51.50 M |
| Levered Free Cash Flow (TTM) | -40.56 M |
| Return on Assets (TTM) | -17.75% |
| Return on Equity (TTM) | -24.47% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | LENZ Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
1.4
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | 1.38 |
|
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 2.76% |
| % Held by Institutions | 92.94% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Ra Capital Management, L.P. | 30 Sep 2025 | 4,178,823 |
| Alpha Wave Global, Lp | 30 Sep 2025 | 3,612,211 |
| Versant Venture Management, Llc | 30 Sep 2025 | 2,656,888 |
| Paradigm Biocapital Advisors Lp | 30 Sep 2025 | 1,073,461 |
| 72 Investment Holdings, Llc | 30 Sep 2025 | 1,017,751 |
| Rtw Investments, Lp | 30 Sep 2025 | 863,389 |
| First Light Asset Management, Llc | 30 Sep 2025 | 693,044 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 67.00 (Piper Sandler, 339.63%) | Buy |
| Median | 58.50 (283.86%) | |
| Low | 50.00 (Raymond James, 228.08%) | Buy |
| Average | 58.50 (283.86%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 37.55 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Raymond James | 20 Oct 2025 | 50.00 (228.08%) | Buy | 36.31 |
| Piper Sandler | 10 Oct 2025 | 67.00 (339.63%) | Buy | 38.79 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 07 Jan 2026 | Announcement | LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates |
| 05 Jan 2026 | Announcement | LENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ™ in the Middle East |
| 01 Dec 2025 | Announcement | LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment of Presbyopia |
| 25 Nov 2025 | Announcement | LENZ Therapeutics to Present at Upcoming Investor Conferences |
| 05 Nov 2025 | Announcement | LENZ Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights |
| 29 Oct 2025 | Announcement | LENZ Therapeutics to Report Third Quarter 2025 Financial Results and Recent Corporate Highlights on November 5, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |